Longitudinal changes in microstructural white matter metrics in Alzheimer's disease
| dc.contributor.author | Mayo, Chantel Dana | |
| dc.contributor.author | Mazerolle, Erin L. | |
| dc.contributor.author | Ritchie, Lesley | |
| dc.contributor.author | Fisk, John D. | |
| dc.contributor.author | Gawryluk, Jodie R. | |
| dc.date.accessioned | 2018-02-14T00:19:41Z | |
| dc.date.available | 2018-02-14T00:19:41Z | |
| dc.date.copyright | 2017 | en_US |
| dc.date.issued | 2017 | |
| dc.description.abstract | Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder. Current avenues of AD research focus on pre-symptomatic biomarkers that will assist with early diagnosis of AD. The majority of magnetic resonance imaging (MRI) based biomarker research to date has focused on neuronal loss in grey matter and there is a paucity of research on white matter. Methods: Longitudinal DTI data from the Alzheimer's Disease Neuroimaging Initiative 2 database were used to examine 1) the within-group microstructural white matter changes in individuals with AD and healthy controls at baseline and year one; and 2) the between-group microstructural differences in individuals with AD and healthy controls at both time points. Results: 1) Within-group: longitudinal Tract-Based Spatial Statistics revealed that individuals with AD and healthy controls both had widespread reduced fractional anisotropy (FA) and increased mean diffusivity (MD) with changes in the hippocampal cingulum exclusive to the AD group. 2) Between-group: relative to healthy controls, individuals with AD had lower FA and higher MD in the hippocampal cingulum, as well as the corpus callosum, internal and external capsule; corona radiata; posterior thalamic radiation; superior and inferior longitudinal fasciculus; fronto-occipital fasciculus; cingulate gyri; fornix; uncinate fasciculus; and tapetum. Conclusion: The current results indicate that sensitivity to white matter microstructure is a promising avenue for AD biomarker research. Additional longitudinal studies on both white and grey matter are warranted to further evaluate potential clinical utility. | en_US |
| dc.description.reviewstatus | Reviewed | en_US |
| dc.description.scholarlevel | Faculty | en_US |
| dc.description.sponsorship | Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The current study was also supported by the Canadian Institutes of Health Research (Competition: 201310): Catalyst Grant for the Secondary Analyses of Neuroimaging Databases and the Canada Graduate Scholarships [grant number CSE 133352]; Natural Sciences and Engineering Research Council of Canada [grant number PDF-454132-2014] and CREATE; Alberta Innovates - Health Solutions [grant number 201300567]. | en_US |
| dc.identifier.citation | Mayo, C.D., Mazerolle, E.L., Ritchie, L., Fisk, J.D. & Gawryluk, J.R. (2017). Longitudinal changes in microstructural white matter metrics in Alzheimer's disease. NeuroImage: Clinical, 13, 330-338. https://doi.org/10.1016/j.nicl.2016.12.012 | en_US |
| dc.identifier.uri | https://doi.org/10.1016/j.nicl.2016.12.012 | |
| dc.identifier.uri | http://hdl.handle.net/1828/9059 | |
| dc.language.iso | en | en_US |
| dc.publisher | NeuroImage: Clinical | en_US |
| dc.subject | Alzheimer's disease | en_US |
| dc.subject | Aging | en_US |
| dc.subject | Diffusion tensor imaging | en_US |
| dc.subject | Magnetic resonance imaging | en_US |
| dc.subject | White matter | en_US |
| dc.title | Longitudinal changes in microstructural white matter metrics in Alzheimer's disease | en_US |
| dc.type | Article | en_US |